Results 1 to 10 of about 9,281 (210)

Investigation of Complement Activation and Cytokine Signatures in AQP4+ NMOSD, MOGAD, and MS. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Aquaporin‐4‐IgG seropositive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), and multiple sclerosis (MS) are pathophysiologically distinct neuroinflammatory disorders. Complement activation is a major mechanism of injury in AQP4+ NMOSD, whereas its role in
Filippatou AG, Dominguez-Penuela S, Acero-Garces D, Gakis G, Smith MD, Resto Y, Reyes-Mantilla M, Chen H, Hernandez I, Said Y, Salazar-Camelo A, Huynh C, Tassoni A, Yednock T, Artis R, Andrews-Zwilling Y, Newsome SD, Saidha S, Bhargava P, Mowry EM, Fitzgerald KC, Calabresi PA, Pardo CA, Sotirchos ES.   +23 more
europepmc   +2 more sources

Efficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders. [PDF]

Ann Clin Transl Neurol
ABSTRACT Background Neuromyelitis optica spectrum disorders (NMOSD) usually occur with acute refractory optic neuritis (ON). However, there is a lack of efficacious treatments to improve recovery. Since fampridine has been found to improve the prognosis of multiple sclerosis (MS) and MS‐related ON, it is necessary to explore the efficacy of fampridine ...
Wang H, Chen W, Li X, Lu H, Li C, Zhang X, Bu L, Xu X, Shen Q, Peng Y.   +9 more
europepmc   +2 more sources

Proportion and Clinical Characteristics of Double-Seronegative NMOSD in a Multicenter Real-World Cohort. [PDF]

Eur J Neurol
ABSTRACT Background Recent 2025 neuromyelitis optica spectrum disorder (NMOSD) criteria distinguish AQP4‐IgG‐positive disease from seronegative‐syndromic groups, into which double‐seronegative‐NMOSD (DN‐NMOSD) may be reclassified, suggesting the need to better characterize DN‐NMOSD within prior diagnostic frameworks.
Hyun JW, Kim KH, Kim SW, Shin HY, Kang YR, Nam TS, Kim W, Kim SH, Kim HJ.   +8 more
europepmc   +2 more sources

The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xu X, Ding J, Du Y, Luo G, Li J, Liu R, Xu X, Li X, Li M, Jiang W, Yang C.   +10 more
europepmc   +2 more sources

Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Gui M, Zhan J, Li W, Jin T, He D, Tian D, Li Z, Lin J, Li Y, Zhou H, Bu B.   +10 more
europepmc   +2 more sources

Opsoclonus-Myoclonus-Ataxia Revealing Underlying Neuromyelitis Optica Spectrum Disorder. [PDF]

Mov Disord Clin Pract
Movement Disorders Clinical Practice, EarlyView.
Verde ASSL, de Paiva Santos Rolim F, Catunda AV, Filho JOFT, Pitombeira MS, Carvalho FMM, de Assis Pereira Matos PCA.   +6 more
europepmc   +2 more sources

Evaluation of Dried Plasma Spot-Based Quantification of Glial Fibrillary Acidic Protein as a Disease-Associated Biomarker in Neuromyelitis Optica Spectrum Disorder. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD).
Wohlrab F, Alvarez E, Hamdi R, Zhang B, Ji H, Jhaveri N, Schindler P, Sanchez P, Sperber PS, Schmitz-Hübsch T, Oertel FC, Vorasoot N, Kissani N, Böhringer F, Kuhle J, Pröbstel AK, Ma XJ, Körtvelyessy P, Waters P, Paul F.   +19 more
europepmc   +2 more sources

The Impact of COVID-19 Infection and Vaccination on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody Disease: A Narrative Review [PDF]

Journal of Central Nervous System Disease
Despite the estimated 776 million coronavirus disease 2019 (COVID-19) cases globally, little is known about its impact on immune-mediated neurological disorders such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte ...
Jeffrey Hernandez DNP, APRN, Silvia Delgado MD, FAAN, Micheline McCarthy MD, PhD, Flavia Nelson MD, Kottil Rammohan MD   +4 more
doaj   +2 more sources

Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology

Annals of Indian Academy of Neurology, 2020
Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological
Bhatia Rohit, M V Padma Srivastava, Dheeraj Khurana, Lekha Pandit, Thomas Mathew, Salil Gupta, M Netravathi, Sruthi S Nair, Gagandeep Singh, Bhim S Singhal   +9 more
doaj   +1 more source

Patients with neuromyelitis optica spectrum disorder (NMOSD) are associated with adverse outcome after total hip arthroplasty: a matched case–control study

Orphanet Journal of Rare Diseases, 2021
Background Neuromyelitis Optica Spectrum Disorders (NMOSD) are rare inflammatory diseases of the central nervous system that cause transverse myelitis and optic neuritis. Steroids are commonly administered in NMOSD patients.
Xi Chen, Wenwei Qian, Guixing Qiu, Xisheng Weng, Jin Lin, Jin Jin, Shibai Zhu, Yiou Wang, Shanni Li   +8 more
doaj   +1 more source